Regeneron Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$41Mgeneral payments (2019-2025)
$14Mresearch payments (2019-2025)
7,910clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Libtayo $2.9M associated (2023-2025)
- Dupixent $2.0M associated (2023-2025)
- Eylea Hd $1.6M associated (2023-2025)
- Eylea $626K associated (2023-2025)
- Lynozyfic $174K associated (2023-2025)
- Evkeeza $116K associated (2023-2025)
- Veopoz $45K associated (2023-2025)
- Praluent $5,170 associated (2023-2025)
- Kevzara $38.83 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Michael Brown | Dallas, TX | Gastroenterology (Internal Medicine) | $5,519,456.79 |
| Joseph Goldstein | Dallas, TX | Clinical Genetics (M.D.) | $5,513,848.52 |
| Huda Zoghbi | Houston, TX | Neurology With Special Qualifications In Child Neurology | $5,454,788.10 |
| Craig Thompson | New York, NY | Medical Oncology | $2,708,149.09 |
| David Schenkein | Boston, MA | Internal Medicine | $2,591,221.14 |
| Joseph Hoffman | Park Ridge, NJ | Pulmonary Disease | $318,712.00 |
| Shawn Kwatra | Baltimore, MD | Dermatology | $280,696.07 |
| Andrew Ji | New York, NY | Dermatology | $250,000.00 |
| Vishal Patel | Leesburg, VA | Dermatology | $169,404.62 |
| Jeffrey Altholz | Elmsford, NY | Internal Medicine | $162,798.75 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.